Association of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer

Richard C. Maduka,Maureen E. Canavan,Samantha L. Walters,Theresa Ermer,Peter L. Zhan,Michael F. Kaminski,Andrew X. Li,Matthew D. Pichert,Michelle C. Salazar,Elizabeth H. Prsic,Daniel J. Boffa
DOI: https://doi.org/10.1002/cam4.7028
IF: 4.711
2024-05-07
Cancer Medicine
Abstract:BLURB FOR ETOC As stated in the manuscript, this study uses de‐identified data from human participants within the National Cancer Database, and the study has been approved by the Yale School of Medicine Institutional Review Board with consent waived. Background Palliative treatment has been associated with improved quality of life and survival for a wide variety of metastatic cancers. However, it is unclear whether the benefits of palliative treatment are uniformly experienced across the US cancer population. We evaluated patterns and outcomes of palliative treatment based on socioeconomic, sociodemographic and treating facility characteristics. Methods Patients diagnosed between 2008 and 2019 with Stage IV primary cancer of nine organ sites were analyzed in the National Cancer Database. The association between identified variables, and outcomes concerning the administration of palliative treatment were analyzed with multivariable logistic regression and Cox proportional hazard models. Results Overall 238,995 (23.6%) of Stage IV patients received palliative treatment, which increased over time for all cancers (from 20.7% in 2008 to 25.6% in 2019). Palliative treatment utilization differed significantly by region (West less than Northeast, OR: 0.55 [0.54–0.56], p
oncology
What problem does this paper attempt to address?